MARKET

HROW

HROW

Harrow Health Inc
NASDAQ
47.32
+1.26
+2.74%
After Hours: 47.24 -0.08 -0.17% 19:30 02/06 EST
OPEN
46.54
PREV CLOSE
46.06
HIGH
48.01
LOW
45.66
VOLUME
512.59K
TURNOVER
--
52 WEEK HIGH
54.85
52 WEEK LOW
20.85
MARKET CAP
1.75B
P/E (TTM)
-310.7026
1D
5D
1M
3M
1Y
5Y
1D
Harrow Health: Building an Integrated Ophthalmic Platform Poised for Accelerated Growth and $1 Billion Run-Rate by 2027
TipRanks · 4d ago
Harrow Gains After Reaffirming FY25 Revenue Guidance
Dow Jones · 5d ago
Lake Street Sticks to Their Buy Rating for Harrow Health (HROW)
TipRanks · 5d ago
Harrow Inc. Files Initial Beneficial Ownership Statement for Chief Commercial Officer Patrick William Sullivan
Reuters · 5d ago
Harrow Health Reaffirms 2025 Outlook, Expands Ophthalmic Platform
TipRanks · 5d ago
Harrow Reiterates 2025 Revenue Outlook Of $270M–$280M Driven By Expanding Commercial Footprint And Portfolio Performance
Benzinga · 5d ago
Harrow reaffirms FY25 revenue view $270M-$280M, consensus $271.18M
TipRanks · 5d ago
*Harrow Backs 2025 Rev $270M-$280M >HROW
Dow Jones · 5d ago
More
About HROW
Harrow, Inc. is a provider of ophthalmic disease management solutions. It offers a portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and retina diseases. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE, BYQLOVI and others. Its product candidates include MELT-210, MELT-300 and MELT-400. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms.

Webull offers Harrow Inc stock information, including NASDAQ: HROW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HROW stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading HROW stock methods without spending real money on the virtual paper trading platform.